Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in mice.

Heart failure remains one of the largest clinical burdens globally, with little to no improvement in the development of disease-eradicating therapeutics. Integrin targeting has been used in the treatment of ocular disease and cancer, but little is known about its utility in the treatment of heart failure. Here we sought to determine whether the second generation orally available, αvβ3-specific RGD-mimetic,

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kairbaan Hodivala-Dilke reports a relationship with Ellipses Pharma that includes: consulting or advisory. Kairbaan Hodivala-Dilke reports a relationship with Vasodynamics that includes: consulting or advisory. Kairbaan Hodivala-Dilke reports a relationship with RGDscience Ltd that includes: consulting or advisory. Horst Kessler and Amnon Hoffman and Michael Weinmuller has patent #WO2019058374A1 pending to YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD [IL]; UNIV MUENCHEN TECH [DE]. Kairbaan Hodivala-Dilke has patent #WO2021032955A1 pending to UNIV LONDON QUEEN MARY [GB]. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.